A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Enrolling
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Trial at a Glance
- Trial ID
- ALN-BCAT-001
- Condition
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Drug/Treatment
- ALN-BCAT, Pembrolizumab
- Does this trial use a placebo?
- No
- Trial Type
- Interventional
- Number of Participants
- 158 participants
- Trial dates
- 2024-12-30 - 2027-10-31
For more information:NCT06600321
Who can participate?
AGE
18+ Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
No
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
